Impact Factor
3.22
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.66
2,455 total citations
h5-index
54
h5 depth signal
Cited share
37.4%
569 of 1,522
Total citations
2,455
Citation footprint
Metric signal
1.77
External metric anchor
Self-citation
7.0%
171 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
3,987
Canada
274
United Kingdom
103
Australia
68
India
45
Citing Fields of Research
Oncology
2,662
Palliative Care
1,238
Patient Care
964
Breast Cancer
665
Health Education & Remote Healthcare
409
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,691
Articles tracked across the journal lifetime
Indexed publication set
1,522
569 cited publications
Last 12 months
1,139
94.9 publications/month
Open access share
3.0%
34 OA publications in the last year
Leading citing country
United States
3,987 citing publications
Leading citing field
Oncology
2,662 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v16n1, Jan. 2020-
v16n1, Jan. 2020-
Research Focus & Classification
Indexed Subjects
Oncology
Palliative Care
Breast Cancer
Patient Care
Lung Cancer
Issuing & Sponsoring Bodies
issuing body
American Society of Clinical Oncology
Broad Categories
Neoplasms
Palliative Care
Patient Care
Medical Ethics
Breast Cancer
Lung Cancer
MeSH Descriptors
Medical Oncology
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1200/op-26-00822
Open DOI
Ambient Artificial Intelligent Scribes in Oncology: Impact on Clinician Experience and Documentation Burden
PURPOSE: Ambient artificial intelligence (AI) scribes, widely implemented to reduce clinician burden and dissatisfaction, are not optimized for oncology. We evaluated this technology at-scale at a high-volume cancer center. METHODS: This...
02
DOI 10.1200/op-26-00935
Open DOI
Reply to: Real World Data and Survival: Bias Is Not Evidence
03
DOI 10.1200/op-26-00690
Open DOI
Reproducibility Status of Economic Evaluations of Cancer Drugs: An Assessment of 150 Cost-Effectiveness Models
Purpose: Model-based cost-effectiveness analyses (CEAs) published in scientific journals have increased in recent years. The studies involve many discretionary judgements that, if not properly reported and justified, may reduce the credi...
04
DOI 10.1200/op-26-00798
Open DOI
Putting the Patient at the Center of Patient-Centered Care
05
DOI 10.1200/op-26-00777
Open DOI
Mapping the Canadian Oncology Physician Workforce: A Review of Training, Distribution, and Systemic Pressures Across Oncology-Related Physician Specialties
Between 1994 and 2020, new cancer cases in Canada increased by 88%, with 40% of the oncology workforce now nearing retirement age. With increasing cancer incidence and an aging workforce, organizations such as the Canadian Association of...
06
DOI 10.1200/op-26-01123
Open DOI
A Decade of QOPI in Spain: From Quality Measurement to Continuous Improvement in Oncology Practice
INTRODUCTION: We evaluated 10 years of QOPI implementation in Spain to characterize quality performance across successive stages of participation, assess sustainability over time, compare performance with contemporaneous QOPI benchmarks,...
07
DOI 10.1200/op-26-00656
Open DOI
Promoting High-Quality, Accessible Cancer Care for People With Disabilities
People with disabilities (PWD) face numerous challenges throughout the continuum of cancer care. Many of these are due to personal and structural biases that have historically made it more difficult for PWD to access oncologic care and w...
08
DOI 10.1200/op-26-00592
Open DOI
When Truth Becomes Asymmetrical: Toxicity, Benefit, and Vulnerable Autonomy in Oncology
09
10
DOI 10.1200/op-26-00217
Open DOI
Participation of Patients With Gynecologic Cancer in Phase I Clinical Trials: Experience From Two National Cancer Institute–Designated Comprehensive Cancer Centers
Purpose: Phase I trials are intended to define the safety of novel therapeutics, yet they offer alternative options long before they are approved. Limited data exist regarding access to and participation in phase I trials among gynecolog...
Bibliographical & Catalog Notes
Some articles in v. 16 published electronically in 2019.
Also issued in print.